198 related articles for article (PubMed ID: 25623548)
1. [Cardiovascular outcome trials in patients with diabetes].
Mannucci E
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):27S-31S. PubMed ID: 25623548
[TBL] [Abstract][Full Text] [Related]
2. [Hypoglycemia and cardiovascular risk].
Avogaro A
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
[TBL] [Abstract][Full Text] [Related]
3. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
[TBL] [Abstract][Full Text] [Related]
4. Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?
Koshizaka M; Green JB; Alexander JH
Circ J; 2012; 76(7):1572-80. PubMed ID: 22789974
[TBL] [Abstract][Full Text] [Related]
5. Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.
Mannucci E; Monami M; Ceriello A; Rotella CM
Nutr Metab Cardiovasc Dis; 2017 Apr; 27(4):375-377. PubMed ID: 28242233
[No Abstract] [Full Text] [Related]
6. Glucose lowering and cardiovascular disease: what do we know and what should we do?
Cheng AY; Leiter LA
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S25-31. PubMed ID: 20489417
[TBL] [Abstract][Full Text] [Related]
7. Glycemic control and cardiovascular mortality.
Riddle MC
Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):104-9. PubMed ID: 21522000
[TBL] [Abstract][Full Text] [Related]
8. [Glycemic targets and cardiovascular morbi-mortality].
Bordier L; Bauduceau B
Presse Med; 2013 May; 42(5):855-60. PubMed ID: 23286961
[TBL] [Abstract][Full Text] [Related]
9. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
[TBL] [Abstract][Full Text] [Related]
10. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
[TBL] [Abstract][Full Text] [Related]
11. Point: Intensive glycemic control and mortality in ACCORD--a chance finding?
Lachin JM
Diabetes Care; 2010 Dec; 33(12):2719-21. PubMed ID: 21115777
[No Abstract] [Full Text] [Related]
12. A cardiologist's view of hypoglycemia.
Nandish S; Wyatt J; Oliveros R; Zion AS; Lujan M; Chilton R
Curr Atheroscler Rep; 2010 Mar; 12(2):88-95. PubMed ID: 20425243
[TBL] [Abstract][Full Text] [Related]
13. Intensive glycemic control and cardiovascular disease: an update.
Brown A; Reynolds LR; Bruemmer D
Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
[TBL] [Abstract][Full Text] [Related]
14. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
Macisaac RJ; Jerums G
Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
[TBL] [Abstract][Full Text] [Related]
15. Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough?
Triplitt C
Consult Pharm; 2010 Jun; 25 Suppl B():19-27. PubMed ID: 20726379
[TBL] [Abstract][Full Text] [Related]
16. Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues.
Riddle MC
Diabetes Care; 2010 Dec; 33(12):2722-4. PubMed ID: 21115778
[No Abstract] [Full Text] [Related]
17. The science of hypoglycemia in patients with diabetes.
Oyer DS
Curr Diabetes Rev; 2013 May; 9(3):195-208. PubMed ID: 23506375
[TBL] [Abstract][Full Text] [Related]
18. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
19. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios.
Prattichizzo F; de Candia P; De Nigris V; Nicolucci A; Ceriello A
Metabolism; 2020 Sep; 110():154308. PubMed ID: 32628943
[TBL] [Abstract][Full Text] [Related]
20. Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.
Huang CJ; Wang WT; Sung SH; Chen CH; Lip GYH; Cheng HM; Chiang CE
Diabetes Obes Metab; 2018 Sep; 20(9):2131-2139. PubMed ID: 29722116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
